欧贝法齐莫德在克罗恩氏病和结肠炎治疗中具有前景,可减少纤维化,并在第二周内诱导缓解,并具有安全性. Obefazimod shows promise for Crohn’s and colitis, reducing fibrosis and inducing remission by week 2 with a safe profile.

在2026年ECCO大会上,Abivax提出了新的数据,显示Obefazimod是克罗恩病和性结肠炎的潜在治疗方法,在人体和动物模型中具有抗纤维作用,可将关键纤维化标志物降低高达50%. Abivax presented new data at the 2026 ECCO Congress showing obefazimod, a potential treatment for Crohn’s disease and ulcerative colitis, has anti-fibrotic effects in human and animal models, reducing key fibrosis markers by up to 50%. 该药物表现出迅速的症状缓解,在临床试验中,到第2周有恢复作用,并且具有类似于安慰剂的有利安全特征。 The drug demonstrated rapid symptom relief, with remission seen by week 2 in clinical trials, and a favorable safety profile similar to placebo. 生物标志的变化包括增加MIR-124和减少IL-17A和IL-6。 Biomarker changes included increased miR-124 and reduced IL-17A and IL-6. 成果支持正在进行的第3阶段和第2b阶段的试验,预计数据为2026年年中。 Results support ongoing Phase 3 and Phase 2b trials, with data expected mid-2026.